Biomx Inc rallies on plan to cut headcount by 50%
** Drug developer's shares PHGE.K jump 15% premarket to
$0.92, set for best session in seven months
** Co intends to reduce headcount by 50% to extend capital
resources, cash expected to last at least till mid-2024 compared
with end 2023 as per previous update urn:newsml:reuters.com:*:nFWN2XF15C
** Flags atopic dermatitis program will be delayed due to
restructuring, but cystic fibrosis program remains on track with
initial data from early stage study expected in Q3
** Stock down 50% YTD as of last close
(Reporting by Susan Mathew)
((susan.mathew@thomsonreuters.com))
Recent news on Tessera Defense and Homeland Security
See all newsBrief: Tessera Defense & Homeland Security - Enters $5 Million Revolving Credit Agreement With Mandragola On Oct 5, 2026 - SEC Filing
Brief: Biomx - Announces One-For-Ten Reverse Stock Split Of Common Stock - SEC Filing
Brief: Biomx And Water.Io Agree To Updated Zorronet Acquisition Terms
Brief: BiomX - May Offer And Sell Up To $9.10 Million Of Common Stock Through Wainwright - SEC Filing
Brief: Biomx Provides Update On Defense Technology Portfolio And Growth Strategy